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Abstract
OBJECTIVE—We sought to assess maternal prenatal use of analgesics and risk of cardiovascular 
malformations (CVM) in the offspring.
STUDY DESIGN—Data from the Baltimore–Washington Infant Study, a population-based case-
control investigation of CVM, were used to examine selected isolated CVM diagnoses and 
maternal analgesic use during the periconceptional period (3 months before and after conception). 
We compared case and control infants on frequency of maternal use of analgesics and estimated 
adjusted odds ratios (adjORs) and 95% confidence intervals (CI) with logistic regression models 
for specific CVM phenotypes.
RESULTS—Frequency of periconceptional use of any analgesic was 52% among control 
mothers and 53% among case mothers. Analyses by CVM diagnoses identified an association of 
tetralogy of Fallot with maternal acetaminophen use (adjOR, 1.6; 95% CI, 1.1–2.3) and 
dextrotransposition of the great arteries with intact ventricular septum with maternal nonsteroidal 
antiinflammatory drug use (adjOR, 3.2; 95% CI, 1.2–8.7).
CONCLUSION—Analgesic use during the periconceptional period was not associated with 
CVM in the aggregate or with most phenotypes of CVM examined. Associations with 2 
phenotypes of CVM may have occurred by chance. These findings warrant corroboration and 
further study, including further evaluation of the observed associations, the dose of analgesic 
taken, more specific timing of analgesic use, and indications for use.
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Analgesic medications are commonly used during pregnancy. Estimates of the prevalence of 
maternal analgesic use during pregnancy have reached ≥70%.1,2 Indications for analgesic 
use are varied and include pain, fever, flu, preterm labor, and certain rheumatologic 
conditions. Analgesics are easily accessed either through prescription or over-the-counter 
purchase. They freely cross the placental barrier, which theoretically could pose potential 
risk to the developing fetus.3 However, while maternal use of analgesics is high, the safety 
of analgesic use during pregnancy has not been well established.
Cardiac morphogenesis is complex and dependent on the expression of multiple genes and 
on many molecular pathways.4 Maternal use of certain medications during fetal 
development, such as anticonvulsants and antihypertensives, has been associated with some 
types of cardiovascular malformations (CVM).5,6 Whether use of analgesics may pose a risk 
is unclear. Many nonopioid analgesics, including salicylates and some other nonsteroidal 
antiinflammatory drugs (NSAIDs), exert their analgesic and antiinflammatory effects 
through inhibition of cyclooxygenase (COX) 1 and 2. It has been hypothesized that COX 
inhibition during the sensitive window of cardiogenesis may be involved in the disruption of 
heart development.7–9 However, epidemiologic studies of the possible association between 
maternal analgesic use and CVM have had varied results.
Given the prevalence of analgesic use during pregnancy, the limited data on the safety of 
analgesic use during pregnancy, and the varied results from existing studies, additional 
evaluation of the possible association between maternal use of the more common analgesics 
and CVM is needed. In this analysis, we used data from the Baltimore–Washington Infant 
Study (BWIS) to examine associations between maternal analgesic use during the 
periconceptional period and CVM phenotypes.
Materials and Methods
The BWIS population consisted of infants born to residents of Maryland, the District of 
Columbia, and 6 adjacent counties of northern Virginia from April 1981 through December 
1989. The methods of this study have been previously described in detail.10,11 All data used 
in our study were deidentified and analyses were performed with an exemption from the 
Institutional Review Board of the Centers for Disease Control and Prevention.
Cases
Cases were infants with any type of CVM ascertained from searches of community 
hospitals, 6 pediatric cardiology centers serving the study region, and the medical 
examiner’s logbooks from Maryland. CVM noted at registration were confirmed by 
echocardiography, cardiac catheterization, surgery, or autopsy. CVM were coded by 
pediatric cardiologists. Updated information about CVM diagnoses at 1 year of age obtained 
for all registered cases resulted in a change in only 7.8% of the initial diagnoses. Infants of 
gestational age<38 weeks with patent ductus arteriosus as the only CVM were not included. 
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Also, because of improvements in diagnostic capability over the study period and the 
resultant rapid rise in the population prevalence among young infants, only a random sample 
of the infants with small ventricular septal defects (VSD) were included in BWIS. Infants 
with >1 cardiac defect were assigned 1 anatomic diagnosis using a hierarchical classification 
approach developed for BWIS based on the presumed embryonic timing of the defects. 
These diagnoses were then placed into categories based on their developmental 
mechanism.10,12 Cases were further classified based on the presence of other anomalies as 
isolated (ie, no noncardiac defects); chromosomal disorders (eg, Down syndrome, other 
trisomies); recognizable syndromes (eg, Ivemark, DiGeorge, Noonan, Williams, fetal 
alcohol, congenital rubella); or multiple defects (ie, with noncardiac anomalies of unknown 
cause).
From all identified CVM cases (n = 4390), we excluded all cases with ≥1 of the following 
factors: maternal reports of pregestational diabetes since this condition is a known risk factor 
for CVM (n = 87); recognized syndromes or chromosomal abnormalities with the exception 
that we included infants with Down syndrome who had atrioventricular septal defect 
(AVSD) (n = 947 excluded); infants who were 1 of a set of twins, triplets, or other multiple 
births (n = 156); and those for whom no maternal interview was obtained (n = 1013). We 
then evaluated singleton infants with isolated CVM whose mothers did not have 
pregestational diabetes and did complete interviews (final n = 2525).
Controls
Controls (n = 3572) were a random sample of all liveborn infants without CVM from the 
same birth cohort who were delivered in participating hospitals, stratified by month, year, 
and hospital of birth. Controls were similar to all area births during the study period by 
infant sex, race, birth weight, plurality, season of birth, and maternal age.13 For this analysis, 
we included interviewed, singleton controls with no CVM, chromosomal anomalies, 
syndromes, or maternal reports of pregestational diabetes (final n = 3435).
Data collection
Home interviews with the parents of case and control infants were conducted within 18 
months of birth of the study subjects. A structured, standardized questionnaire was 
administered by trained interviewers to obtain information on sociodemographic factors, 
family history, maternal medical conditions, and environmental factors. The latter included 
reports on medication use during the periconceptional period (3 months before the last 
menstrual period through the first trimester of pregnancy).
Analgesic use
For this analysis, we defined exposure as maternal use of an analgesic-containing 
medication at any time during the periconceptional period to ensure that all relevant 
exposures were included regardless of errors in recall of the last menstrual period or in recall 
of the exact timing of medication use. Maternal reports of use of prescription and 
nonprescription analgesics during the periconceptional period were grouped into 
pharmacologic classes: salicylates, acetaminophen, other NSAIDs, and opioids.
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First, we compared the frequency of selected maternal and infant demographic and clinical 
characteristics among cases and controls using the χ2 statistic. A χ2 statistic was not 
calculated if the proportion of subjects with missing values was >5% of the total. Then, 
because the presence of maternal fever or flu symptoms has been associated with an 
increased risk of CVM in the infant in previous analyses of BWIS data, we examined the 
frequency of maternal analgesic use among case and control infants by pharmacologic class 
stratified by the presence of fever or maternal flu symptoms during the periconceptional 
period.5,10 Finally, we used multiple logistic regression models to evaluate possible 
associations of selected specific CVM diagnostic groups with maternal periconceptional use 
of analgesics by pharmacologic class using adjusted odds ratios (adjORs) and 95% 
confidence intervals (CIs). For this part of the analysis, we excluded infants of mothers who 
reported use of >1 class of analgesic drug, including use of single preparations that 
contained >1 class of analgesic, during the periconceptional period (28%of cases and27%of 
controls). However, infants of mothers who reported use of nonanalgesic drugs only, or use 
of single preparations that contained both an analgesic and a nonanalgesic drug, during the 
periconceptional period were included. All models were adjusted for the covariates of infant 
sex, infant race, maternal age, family history of CVM, family history of other birth defects, 
maternal fever or flu symptoms during the periconceptional period, maternal prepregnancy 
body mass index (weight in kilograms/height in m2), and maternal smoking during the 
periconceptional period, with inclusion of quadratic terms for maternal age and 
prepregnancy body mass index because of their potential nonlinear relationship with the risk 
for birth defects. Only subjects with nonmissing values for all covariates were included in 
the models. We considered only associations based on at least 3 exposed cases to be stable.
Results
Characteristics of case and control infants
Compared with control infants, case infants were significantly more likely to have a family 
history of CVM (P <.001). Otherwise, case and control infants were similar with respect to 
maternal and infant demographic and clinical characteristics (Table 1).
Maternal analgesic use
From April 1981 through December 1989, the BWIS enrolled and interviewed 2525 
singleton infants with isolated CVM or with AVSD and Down syndrome and 3435 singleton 
infants with no CVM, chromosomal anomalies, or syndromes whose mothers did not have 
pregestational diabetes. The frequency of any analgesic use during the periconceptional 
period was 53% among case mothers and 52% among control mothers. The frequency of 
analgesic use by pharmacologic class among case and control mothers, respectively, was: 
any salicylate-containing medication, 13.5% and 12.1%; any acetaminophen-containing 
medication, 42.9% and 43.5%; any NSAID-containing medication, 8.8%and 8.6%; and any 
opioid-containing medication, 4.4% and 3.6%. Among mothers of case infants who reported 
fever or flu symptoms during the periconceptional period, 177 (67.3%) used an analgesic 
compared with 235 (70.1%) among mothers of control infants who reported fever or flu 
symptoms (Table 2). Among mothers of case infants who did not report fever or flu 
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symptoms during the periconceptional period, 1160 (51.3%) used an analgesic compared 
with 1560 (50.3%) among mothers of control infants who did not report fever or flu 
symptoms. Overall, analgesic use was similar among mothers of case and control infants for 
all pharmacologic categories when stratified by the presence of fever or flu symptoms.
CVM diagnostic groups and maternal analgesic use
When comparing use of analgesics by pharmacologic class and case or control status, 
multiple logistic regression analyses showed few significant associations between analgesic 
use and CVM (Table 3). Mothers of infants with tetralogy of Fallot were significantly more 
likely to have used acetaminophen during the periconceptional period than were control 
mothers (adjOR, 1.57; 95% CI, 1.08–2.27); mothers of infants with dextrotransposition of 
the great arteries (dTGA) with intact ventricular septum were significantly more likely to 
have used NSAIDs during the periconceptional period (adjOR, 3.24; 95% CI, 1.19–8.77). 
Maternal use of salicylates or opioids during the periconceptional period was not associated 
with CVM in the offspring.
Comment
We found that use of any analgesic during the periconceptional period was common among 
pregnant women enrolled in BWIS, with the most commonly used analgesic class being 
medications containing acetaminophen. Analgesic use did not differ by the presence of fever 
or flu symptoms. Consistent with prior knowledge of congenital cardiac defects,14 we found 
that family history of cardiac malformation was associated with increased prevalence of 
CVM in the offspring. Although analgesic use in the periconceptional period was not 
associated with CVM in the aggregate, we found associations of specific CVM phenotypes 
with maternal periconceptional use of acetaminophen and NSAID.
An association of CVM with periconceptional NSAID or acetaminophen use is consistent 
with the hypothesis that COX inhibition during fetal heart development might increase the 
risk of CVM in the infant. However, if COX inhibition were the underlying cause, one 
would expect that fetal exposure to irreversible inhibition of COX isoforms by salicylate 
during the critical period would also result in CVM. We did not observe an association 
between salicylate use and CVM.
Prior studies examining the association between exposure to COX inhibitors during the 
critical period of heart development and CVM have had mixed findings. In animal studies, 
use of high-dose aspirin and NSAIDs has been associated with cardiac septal defects. 15,16 
In human beings, data from the Collaborative Perinatal Project, a prospective cohort study, 
showed no association of aspirin use early in pregnancy with CVM in the aggregate.17 
Similarly, findings from a case-control study by Werler et al18 showed no association of 
aspirin use with CVM in the aggregate (relative risk, 0.9; 95% CI, 0.8–1.1). However, a 
slight association between maternal NSAID use during gestational weeks 5–8 and atrial 
septal defects was seen in a prospective cohort study from Norway, although the findings 
were not statistically significant (adjOR, 1.6; 95% CI, 0.7–3.9).19 Data based on the 
Swedish Birth Registry suggested an association between NSAID use and CVM in the 
aggregate (OR, 1.86; 95% CI, 1.32–2.62).20 A Canadian Registry–based study also found an 
Marsh et al. Page 5













association between maternal NSAID use in the first trimester and cardiac septal defects 
(OR, 3.34; 95% CI, 1.87–5.98).21
Prospective data from the Danish National Birth Cohort and case-control data from the 
National Birth Defects Prevention Study (NBDPS) showed no increased risk of CVM with 
acetaminophen use.22,23 In addition, no significant associations were noted between 
muscular VSD and maternal use of either NSAIDs or acetaminophen, adjusting for maternal 
fever, in NBDPS data.24 However, more recent reports from this study have shown 
associations of maternal use of opioid analgesics with all CVM in the aggregate as well as 
with specific cardiac defects (ie, AVSD without Down syndrome, tetralogy of Fallot, 
conoventricular septal defect, hypoplastic left heart syndrome, pulmonary valve stenosis, 
and atrial septal defect + VSD and pulmonary valve stenosis + VSD associations), and of 
maternal use of naproxen with isolated pulmonary valve stenosis among full-term 
infants. 25,26 A recent study from The Norwegian Mother and Child Cohort Study found no 
association between maternal codeine use in the first trimester and congenital anomalies in 
the offspring.27
Previous analyses of BWIS data focusing on possible risk factors for each cardiac phenotype 
found associations of maternal periconceptional use of ibuprofen (1 type of NSAID) with 
dTGA with intact ventricular septum and with AVSD among infants with Down syndrome, 
and use of aspirin with interrupted aortic arch.10,28 We did not include interrupted aortic 
arch in our study due to its strong association with DiGeorge syndrome. Our analysis, which 
excluded infants with chromosomal anomalies and any noncardiac birth defects, also 
showed an association between dTGA with intact ventricular septum and maternal NSAID 
use.
Among the cardiac phenotypes common to the recent report on opioid exposure from 
NBDPS and ours (ie, AVSD without Down syndrome, tetralogy of Fallot, hypoplastic left 
heart syndrome, and pulmonary valve stenosis), we found no associations with opioid 
analgesics. Possible reasons for the difference in findings between the 2 studies include a 
smaller sample size for each specific cardiac phenotype in our study; possible differences in 
composition between the opioid analgesics used during the different time periods (ie, 1981 
through 1989 vs 1997 through 2005), the amount of opioid used, concomitant use of other 
medications, or the indication for use; and possible sampling variation.
Our findings need to be viewed in light of the limitations and strengths of the study. 
Limitations include potential maternal recall bias due to self-reported exposure status. 
However, >90% of the home interviews for both cases and controls were completed within 
12 months of the infant’s birth and the interview questions related drug use to specific 
medical indications.10,29 A low likelihood of recall bias is also suggested by a previous 
analysis of reported drug use within the BWIS data, which showed no significant differences 
between the number of drugs reported by the time elapsed between delivery and 
interview. 13 As the time period of exposure spans up to 3 months before the last menstrual 
period, there may be a bias towards the null, as the half-life of most analgesics is <30 
hours.30 Another limitation pertains to the lack of information regarding the maternal dose 
of analgesic used, which prevented us from examining dose-response for any of the 
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pharmacologic classes of analgesics. There were also a small number of women using 
isolated opioid medications during the preconceptional period in our study, which prohibited 
us from assessing associations of many CVM types with maternal opioid use. We did not 
have information on some of the newer analgesic classes, such as COX-2 inhibitors, which 
were not widely used during the period of the BWIS. In addition, we included mothers who 
used nonanalgesic medications and could not control for possible differential exposure to 
these drugs between case and control infants. We were not able to assess any potential joint 
effects of these preparations because of the small number of mothers who reported taking 
individual multicomponent preparations. Confounding by indication is another potential 
limitation.
There were also some nonspecific categories of medication use reported in the BWIS data, 
such as miscellaneous cold medicines, and some reports of medication use for which the 
drug name was not known; these were not included in our exposure definition but might 
have contained analgesics and could have resulted in exposure misclassification. To assess 
the impact of maternal illness, we performed analyses controlling for the presence of 
maternal fever or flu symptoms as proxies for hyperthermia and influenza. However, some 
maternal infections might have been subclinical or underreported resulting in residual 
confounding. Also, we made no statistical corrections for multiple comparisons, which may 
have resulted in our finding of 2 significant associations due to chance alone. With the 
number of statistical comparisons made, approximately 4 significant findings would be 
expected due to chance and not to truly significant associations. Finally, the BWIS data are 
>20 years old, and the pattern of analgesic use may have changed over that time. However, 
use of analgesics is still common and indications for use have not changed significantly 
during the intervening period.
Strengths of our study include the population-based design of BWIS, which can minimize 
the potential for selection bias. Also, cases were identified from multiple sources, which 
maximized ascertainment. Other strengths are the classification of CVM in this study that 
took embryonic origin into account and was reviewed by pediatric cardiologists, and the 
verification of CVM diagnoses by echocardiogram, catheterization, or surgery for all case 
infants, which allowed evaluation of possible associations of analgesic use with specific 
phenotypes. In addition, we classified all analgesics by their pharmacologic mechanism, 
which allowed evaluation of biologically plausible associations between maternal analgesic 
use and CVM. Finally, we examined maternal analgesic use during the periconceptional 
period of organogenesis when potential teratogens would be expected to affect cardiac 
development.
Our findings provide reassurance that maternal analgesic use during pregnancy does not 
result in major teratogenic effects relative to congenital heart defects. We did find 
suggestion of a possible association of maternal use of NSAIDs and acetaminophen during 
the periconceptional period with dTGA with intact ventricular septum and tetralogy of Fallot 
in the offspring, respectively. Further studies are warranted to replicate these findings. 
Future studies regarding the potential teratogenicity of analgesics also should include 
information on dose and the specific timing of use; evaluate the use of newer analgesic 
classes such as COX-2 inhibitors; and attempt to limit exposure to the period of cardiac 
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development while taking into account the half-life of the drugs, their excretion, and their 
indication for use.
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TABLE 2
Maternal analgesic use by analgesic class during periconceptional perioda
Analgesic class Cases (n = 2525) % Controls (n = 3435) %
No fever or flu symptoms 2262 100 3100 100
 No analgesic drugs 1102 48.7 1540 49.7
 Any analgesic drug 1160 51.3 1560 50.3
 Any aspirin-containing drug 295 13.0 359 11.6
 Aspirin only 127 5.6 171 5.5
 Any acetaminophen-containing drug 935 41.3 1296 41.8
 Acetaminophen only 649 28.7 905 29.2
 Any NSAID 190 8.4 257 8.3
 NSAID only 51 2.3 60 1.9
 Any opioid-containing drug 94 4.2 100 3.2
 Opioid drug only 8 0.4 7 0.2
With fever and/or flu symptoms 263 100 335 100
 No analgesic drugs 86 32.7 100 29.9
 Any analgesic drug 177 67.3 235 70.1
 Any aspirin-containing drug 46 17.5 57 17.0
 Aspirin only 16 6.1 23 6.9
 Any acetaminophen-containing drug 149 56.7 199 59.4
 Acetaminophen only 100 38.0 136 40.6
 Any NSAID 33 12.5 37 11.0
 NSAID only 9 3.4 7 2.1
 Any opioid-containing drug 16 6.1 23 6.9
 Opioid drug only 1 0.4 4 1.2
NSAID, nonsteroidal antiinflammatory drug.
a
Singleton infants of mothers without pregestational diabetes who completed interviews–infants with major noncardiac organ system anomalies, 
recognized syndromes, or chromosomal abnormalities other than Down syndrome with atrioventricular septal defects were excluded.
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